Zacks Investment Research on MSN

AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

Axsome Therapeutics AXSM incurred a loss of 94 cents per share in the third quarter of 2025, wider than the Zacks Consensus ...

Axsome anticipates expanded market access for SYMBRAVO and AUVELITY while advancing late-stage pipeline

Q3 2025 Management View CEO Herriot Tabuteau stated that "Axsome continues to lead in CNS innovation, driven by disciplined ...

Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growthAUVELITY® 3Q 2025 net product sales of $136.1 million, ...
Business Insider

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI ®, AUVELITY ®, and ... necessary to support the filing of ...
AOL

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years

Axsome Therapeutics' lineup already has strong momentum, and things will get better as it earns new approvals. Exelixis has found tremendous success with Cabometyx and is already looking for its ...